Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | TKT | P29401 | 7/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PPP5C | P53041 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9766249 | 1.00 | LMNA (0.94) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19138210 | 0.99 | LMNA (0.93) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Phosphoric Acid SCHEMBL991151 | 0.99 | LMNA (0.93) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| SCHEMBL675863 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| SCHEMBL29465135 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| SCHEMBL9766253 | 0.99 | LMNA (0.96) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL23151779 | 0.98 | LMNA (0.94) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Bromide SCHEMBL23151782 | 0.98 | LMNA (0.94) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL21111 | 0.98 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 | |
| Cocarboxylase SCHEMBL8923435 | 0.98 | LMNA (0.98) | LMNATKTTDP1HSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 791 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024106663-A1 | COMPOSITION FOR REDUCING METHANE EMISSION FROM RUMINANTS CONTAINING THIAMINE TRIPHOSPHATE | 대한민국(농촌진흥청장) | 2024-05-23 | — | — | WO | claimed |
| CN-113402555-B | Preparation method of cocarboxylase and tetrahydrate or salt thereof | 上海医药工业研究院 | 2022-12-30 | — | — | CN | claimed |
| US-20220370449-A1 | COMBINED PHARMACEUTICAL COMPOSITION | GIDD COMMERCIAL USA, INC. | 2022-11-24 | — | — | US | claimed |
| US-20220279831-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS FRANCE (FR) | 2022-09-08 | — | — | US | claimed |
| US-11406636-B2 | Combined pharmaceutical composition | GIDD COMMERCIAL USA, INC. (US) | 2022-08-09 | — | — | US | claimed |
| US-20220079201-A1 | COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION | EXELTIS FRANCE (FR) | 2022-03-17 | — | — | US | claimed |
| US-11266743-B2 | Peptide compositions and methods of use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-03-08 | — | — | US | claimed |
| US-11248156-B2 | Borehole fluid with a thiamine-based shale inhibitor | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-02-15 | — | — | US | claimed |
| CN-113402555-A | Preparation method of cocarboxylase and tetrahydrate or salt thereof | 上海医药工业研究院 | 2021-09-17 | — | — | CN | claimed |
| WO-2021066811-A1 | BOREHOLE FLUID WITH A THIAMINE-BASED SHALE INHIBITOR | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| CN-1173984-C | Purification method of thiamine phosphate | Ĭ��ר���ɷ�����˾ | 2004-11-03 | — | — | CN | claimed |
| US-6746678-B1 | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments | SECANT PHARMA, LLC | 2004-06-08 | — | — | US | claimed |
| US-20030180396-A1 | Method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate | INSTITUT PASTEUR (FR) | 2003-09-25 | — | — | US | claimed |
| US-6596865-B1 | Removing phosphoric acid and thiamine triphosphate by flowing over unsaturated nitrogen-heterocycle resin adsorber | MERCK PATENT GMBH (DE) | 2003-07-22 | — | — | US | claimed |
| EP-1140953-B1 | METHOD OF PURIFYING THIAMINE PHOSPHATES | MERCK PATENT GMBH (DE) | 2003-01-22 | — | — | EP | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| EP-1229919-A2 | A METHOD OF EFFECTING PHOSPHORYLATION IN EUCARYOTIC CELLS USING THIAMINE TRIPHOSPHATE | INSTITUT PASTEUR (FR) | 2002-08-14 | — | — | EP | claimed |
| CN-1330657-A | Purification method of thiamine phosphate | MERCK PATENT GMBH (DE) | 2002-01-09 | — | — | CN | claimed |
| WO-2001010444-A2 | A METHOD OF EFFECTING PHOSPHORYLATION IN EUCARYOTIC CELLS USING THIAMINE TRIPHOSPHATE | INSTITUT PASTEUR (FR) | 2001-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | LMNA 1677/4885TKT 501/4885TDP1 3154/4885 |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | RBP4, RBP1, VDR | LMNA 97/4885TKT 4628/4885TDP1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.